Myasthenia Gravis
Introduction
Myasthenia Gravis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating skeletal muscle weakness and fatigability. The disease results from autoantibodies targeting proteins at the neuromuscular junction (NMJ), most commonly the nicotinic acetylcholine receptor (AChR), leading to impaired neuromuscular transmission. MG is the most common primary disorder of neuromuscular transmission, with a worldwide prevalence of approximately 150-250 per million and an annual incidence of 8-30 per million ([Gilhus et al., 2019](https://doi.org/10.1038/s41572-019-0079-y)). [@carr2010]
Although MG is not a classical neurodegenerative disease, it shares pathogenic mechanisms with neurodegeneration including autoimmune-mediated destruction at neural synapses, complement-mediated tissue damage, and progressive functional decline. Its study has advanced understanding of autoimmune mechanisms at synapses relevant to conditions like [autoimmune-encephalitis](/diseases/autoimmune-encephalitis) and [neuromyelitis-optica](/diseases/neuromyelitis-optica). [@drachman1994]
Epidemiology
MG has a bimodal age distribution: [@hoch2001]
- Early-onset MG (EOMG): Peak incidence in the 2nd-3rd decades, female predominance (3):1), strongly associated with thymic hyperplasia and anti-AChR antibodies
- Late-onset MG (LOMG): Peak incidence after age 50, slight male predominance, associated with thymic atrophy and anti-AChR antibodies, increasingly recognized as the most common form due to aging populations
The overall incidence is increasing, partly due to improved diagnostic awareness and aging demographics. MG prevalence estimates have risen from 5-15 per 100,000 historically to 15-25 per 100,000 in recent studies, reflecting both true increases and improved case ascertainment ([Carr et al., 2010](https://doi.org/10.1136/jnnp.2008.169037)). [@gilhus2024]
Pathophysiology
Antibody Subtypes and Mechanisms
Anti-AChR Antibodies (80-85% of generalized MG)
Anti-AChR antibodies are predominantly IgG1 and IgG3 subclasses that cause neuromuscular junction damage through three main mechanisms ([Drachman, 1994](https://doi.org/10.1056/NEJM199406233302507)): [@gilhus2025]
Complement activation: Anti-AChR antibodies activate the classical complement pathway, forming membrane attack complexes (MAC, C5b-9) on the postsynaptic membrane. This destroys the NMJ endplate architecture, reducing the number of functional AChRs and simplifying postsynaptic folds. Complement deposition is the primary pathogenic mechanism in most patients.
Antigenic modulation (receptor cross-linking): Divalent IgG antibodies cross-link adjacent AChR molecules, accelerating their internalization and lysosomal degradation. This increases the rate of AChR turnover 2-3 fold, exceeding the rate of new receptor synthesis.
Functional blockade: Some antibodies bind directly to the [acetylcholine](/entities/acetylcholine) binding site on the AChR α-subunit, competitively blocking neurotransmitter binding.Anti-MuSK Antibodies (5-8% of generalized MG)
Muscle-specific kinase (MuSK) antibodies are predominantly IgG4, which does not activate complement. Instead, anti-MuSK antibodies disrupt the agrin–LRP4–MuSK signaling complex essential for AChR clustering at the NMJ: [@howard2021]
- MuSK normally signals through downstream kinases to anchor AChRs at the postsynaptic membrane via rapsyn
- Anti-MuSK antibodies block the MuSK–LRP4 interaction, preventing agrin-induced AChR clustering
- This leads to dispersal of AChRs from the NMJ and impaired synaptic transmission
- MuSK-MG tends to have more bulbar and respiratory involvement, with less response to acetylcholinesterase inhibitors ([Hoch et al., 2001](https://doi.org/10.1038/nm0601_365))
Anti-LRP4 Antibodies (1-3%)
Low-density lipoprotein receptor-related protein 4 (LRP4) antibodies, identified more recently, block the agrin–LRP4 interaction upstream of MuSK, similarly disrupting AChR clustering. [@wolfe2016]
Seronegative MG (5-10%)
Some patients with clinical MG test negative for all three antibody types using standard assays. Some may have low-affinity or cell-based assay-detectable antibodies against clustered AChRs not detected by solution-phase radioimmunoassay. [@zhou2025]
Thymic Pathology
The thymus plays a central role in the immunopathogenesis of AChR-MG: [@verschuuren2025]
- Thymic hyperplasia (50-70% of EOMG): Germinal centers within the thymus contain B cells that produce anti-AChR antibodies. Thymic myoid cells express AChR and may serve as the autoantigen source for initiating the autoimmune response.
- Thymoma (~15% of MG patients): Thymic epithelial tumors that export autoreactive T cells. Thymoma-associated MG (TAMG) often presents with more severe, treatment-resistant disease and may include additional autoimmune comorbidities. Approximately 30-50% of thymoma patients develop MG.
Safety Factor and Neuromuscular Transmission
Normal neuromuscular transmission has a large safety factor—the amount of [acetylcholine](/entities/acetylcholine) released far exceeds the minimum required to trigger a muscle fiber action potential. In MG, the combination of reduced AChR density, simplified postsynaptic folds (loss of voltage-gated sodium channels), and widened synaptic clefts reduces this safety factor. With repetitive stimulation, progressive depletion of presynaptic acetylcholine vesicles causes the endplate potential to fall below the threshold for muscle fiber activation, producing the characteristic fatigable weakness. [@meriggioli2009]
Clinical Presentation
Cardinal Features
- Fluctuating weakness: Weakness worsens with activity and improves with rest
- Fatigability: Progressive decline in muscle force during sustained or repetitive use
- Diurnal variation: Symptoms typically worsen toward the end of the day
Subtypes
| Subtype | Frequency | Features | [@lazaridis2020]
|---------|-----------|----------|
| Ocular MG | 15-20% | Ptosis, diplopia only; 50% progress to generalized within 2 years |
| Generalized MG | 80-85% | Limb, bulbar, respiratory, and/or axial muscle involvement |
| Bulbar-onset MG | 15-20% | Dysarthria, dysphagia, nasal speech as initial symptoms |
| MuSK-MG | 5-8% | Prominent bulbar, facial, and neck weakness; respiratory crises more common |
Myasthenic Crisis
Myasthenic crisis is a life-threatening exacerbation featuring respiratory failure requiring mechanical ventilation. It occurs in 15-20% of MG patients and can be triggered by infections, surgery, certain medications (aminoglycosides, beta-blockers, checkpoint inhibitors), or medication changes. Mortality has decreased from >30% to <5% with modern ICU management.
Diagnosis
Clinical Examination
- Ice pack test: Placing ice on a ptotic eyelid for 2 minutes improves ptosis (cooling improves neuromuscular transmission)
- Repetitive nerve stimulation (RNS): Delivers trains of electrical stimuli at 2-3 Hz; a decremental response (>10% amplitude decline) indicates impaired NMJ transmission
- Single-fiber electromyography (SFEMG): Most sensitive test (>95%), detecting increased jitter and blocking in affected muscles
Serological Testing
- Anti-AChR antibodies: Radioimmunoassay (RIA), positive in ~85% of generalized MG and ~50% of ocular MG
- Anti-MuSK antibodies: Cell-based assay, positive in 5-8% of generalized MG
- Anti-LRP4 antibodies: Available at specialized centers
- Cell-based assays for clustered AChR: More sensitive than RIA, detecting additional cases
Imaging
- CT/MRI of the anterior mediastinum: To evaluate for thymoma
- All newly diagnosed MG patients should undergo thymic imaging
Treatment
Symptomatic Therapy
Acetylcholinesterase inhibitors: Pyridostigmine (Mestinon) is the first-line symptomatic treatment, inhibiting acetylcholine breakdown at the NMJ and prolonging receptor activation. Dose: typically 60-120 mg every 4-6 hours. Less effective in MuSK-MG and may worsen fasciculations.
Immunosuppressive Therapy
- Corticosteroids: Prednisone/prednisolone remain the mainstay initial immunosuppressive treatment. High-dose initiation carries risk of transient worsening (steroid dip).
- Azathioprine: First-line steroid-sparing agent; 2-3 mg/kg/day. Takes 6-18 months for full effect. Check TPMT genotype before initiating.
- Mycophenolate mofetil: Second-line steroid-sparing agent; 2-3 g/day in divided doses.
- Methotrexate: Alternative steroid-sparing agent.
- Tacrolimus/cyclosporine: Calcineurin inhibitors; used as alternatives or add-on therapy.
Targeted Biological Therapies
The treatment landscape for MG has been transformed by targeted biologics ([Gilhus et al., 2024](https://doi.org/10.1111/ene.16229)):
Complement Inhibitors
- Eculizumab (Soliris): Monoclonal antibody against C5, preventing MAC formation. FDA-approved for anti-AChR+ generalized MG (2017). Reduces exacerbations and improves daily function.
- Ravulizumab (Ultomiris): Long-acting anti-C5 antibody with extended dosing interval (every 8 weeks vs. every 2 weeks for eculizumab). FDA-approved 2022.
- Zilucoplan: Subcutaneously administered small macrocyclic peptide terminal complement (C5) inhibitor, available from February 2024, offering a non-infusion option ([Gilhus et al., 2025](https://doi.org/10.1007/s00415-025-12922-7)).
Neonatal Fc Receptor (FcRn) Inhibitors
FcRn normally recycles IgG antibodies back into circulation, maintaining their long half-life. FcRn inhibitors accelerate IgG catabolism, rapidly reducing pathogenic antibody levels:
- Efgartigimod (Vyvgart): IgG1 Fc fragment that competitively blocks FcRn. FDA-approved for anti-AChR+ generalized MG (2021). Available IV and SC formulations. Achieves rapid and sustained improvement in most patients ([Howard et al., 2021](https://doi.org/10.1016/S1474-4422(21)00159-9)). Also being studied for MuSK-MG ([Zhou et al., 2025](https://doi.org/10.1177/17562864251326778)).
- Rozanolixizumab (Rystiggo): Humanized IgG4 monoclonal antibody against FcRn. First FDA-licensed agent approved for both AChR+ and MuSK+ generalized MG (2023). Subcutaneous administration.
B-Cell Depletion
- Rituximab: Anti-CD20 monoclonal antibody. Particularly effective in MuSK-MG (sustained remission in >70% of patients). Less consistent results in AChR-MG, though two RCTs have been completed ([Gilhus et al., 2025](https://doi.org/10.1007/s00415-025-12922-7)).
Thymectomy
Thymectomy is recommended for:
- All MG patients with thymoma (regardless of antibody status)
- Non-thymomatous anti-AChR+ generalized MG patients aged 18-65 years
The MGTX trial demonstrated that thymectomy combined with prednisone achieved better clinical outcomes, lower prednisone requirements, and fewer immunosuppressive treatments than prednisone alone over 3 years ([Wolfe et al., 2016](https://doi.org/10.1056/NEJMoa1602489)).
Rescue Therapies for Acute Exacerbations
- Plasma exchange (PLEX): Rapidly removes circulating antibodies; effects within days but temporary (weeks)
- Intravenous immunoglobulin (IVIg): Modulates immune response through multiple mechanisms; typical dose 2 g/kg over 2-5 days
Prognosis
With modern treatment, most MG patients achieve good functional outcomes:
- Pharmacological remission: 10-15% achieve complete stable remission off all treatment
- Minimal manifestation status: 40-60% achieve minimal symptoms on treatment
- Treatment-resistant: 10-15% remain significantly disabled despite optimal therapy
Mortality has improved dramatically, from ~30% in the pre-treatment era to <5% in the modern era, primarily related to myasthenic crisis and treatment complications.
Current Research Directions
Biomarker-guided treatment selection: Using antibody subtypes, complement activity markers, and AChR clustering assays to select the optimal targeted therapy for individual patients
CAR-T cell therapy: Chimeric antigen receptor T cells engineered to deplete AChR-specific B cells, potentially offering long-term remission
Tolerogenic approaches: Inducing immune tolerance to AChR through nanoparticle delivery of AChR epitopes or regulatory T cell therapy
MuSK-MG-specific therapies: Better understanding of the IgG4-mediated pathogenesis is guiding development of targeted treatments
Checkpoint inhibitor-induced MG: Understanding and managing MG triggered by cancer immunotherapy (anti-PD-1/PD-L1 and anti-CTLA-4), which is often severe and refractorySee Also
Background
The study of Myasthenia Gravis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
Recent Research (2024-2026)
Recent advances in Myasthenia Gravis have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:
- Genetic studies: Identification of new genetic risk factors and mechanistic insights
- Biomarker research: Development of diagnostic and prognostic biomarkers
- Therapeutic approaches: Investigation of novel treatment strategies
- Clinical trials: Ongoing Phase I-III trials for new therapies
References
[Unknown, Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. [DOI (2019)](https://doi.org/10.1038/s41572-019-0079-y)
[Unknown, Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46. [DOI (2010)](https://doi.org/10.1186/1471-2377-10-46)
[Unknown, Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797-1810. [DOI (1994)](https://doi.org/10.1056/NEJM199406233302507)
[Unknown, Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365-368. [DOI (2001)](https://doi.org/10.1038/nm0601_365)
[Gilhus NE, Verschuuren JJ, Hovels-Gurich HH, et al., Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. Eur J Neurol. 2024;31(6):e16229. [DOI (2024)](https://doi.org/10.1111/ene.16229)
[Gilhus NE, et al., Myasthenia gravis in 2025: five new things and four hopes for the future. J Neurol. 2025;272:207. [DOI (2025)](https://doi.org/10.1007/s00415-025-12922-7)
[Howard JF Jr, Bril V, Vu T, et al, Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT]: a multicentre, randomised, placebo-controlled, phase 3 trial (2021)](/[DOI:10.1016/S1474-4422(21)(https://doi.org/10.1016/S1474-4422(21))
[Wolfe GI, Kaminski HJ, Aban IB, et al., Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511-522. [DOI (2016)](https://doi.org/10.1056/NEJMoa1602489)
[Zhou Y, Zhou Q, Yue Y, et al., Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis. Ther Adv Neurol Disord. 2025;18:17562864251326778. [DOI (2025)](https://doi.org/10.1177/17562864251326778)
[Verschuuren JJGM, et al., Myasthenia gravis with antibodies against the AChR: current knowledge on pathophysiology and an update on treatment strategies with special focus on targeting plasma cells. Autoimmun Rev. 2025;24(6):103729. [DOI (2025)](https://doi.org/10.1016/j.autrev.2025.103729)
[Unknown, Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475-490. [DOI (2009)](https://doi.org/10.1016/S1474-4422(09)
[Unknown, Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020;11:212. [DOI (2020)](https://doi.org/10.3389/fimmu.2020.00212)